A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics

PURPOSE: Abiraterone acetate is used at a fixed oral dose of 1000 mg once daily (OD) taken fasted. By administering abiraterone acetate with food, a reduced dose can potentially be given while maintaining equivalent abiraterone exposure. Moreover, administering abiraterone acetate with a breakfast i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Lubberman, Floor J. E., Benoist, Guillemette E., Gerritsen, Winald, Burger, David M., Mehra, Niven, Hamberg, Paul, van Oort, Inge, van Erp, Nielka P.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820614/
https://ncbi.nlm.nih.gov/pubmed/31515667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03952-w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars